Clinical trial
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
NCT00088530 · CTI BioPharma, Industry · Completed
Key facts
| NCT number | NCT00088530 |
|---|---|
| Title | BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) |
| Official title | Pixantrone (BBR 2778) Versus Other Chemotherapeutic Agents for Third-line Single Agent Treatment of Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma: A Randomized, Controlled, Phase III Comparative Trial |
| Lead sponsor | CTI BioPharma, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin |
| Intervention type | Drug |
| Interventions | pixantrone, cyclophosphamide, vincristine, rituximab, prednisone, Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone and 1 more |
| Enrollment | 140 |
| Start date | Jul 1, 2004 |
| Primary completion | Feb 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Jul 29, 2004 |
| Last update posted | Feb 5, 2020 |
| Countries | Argentina, Bulgaria, Costa Rica, Ecuador, Estonia, France, Germany, Hungary, India, Italy, Mexico, Panama and 8 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: